**WHRI Website:**

**Research Project Template**

Please complete one form per research project/program you would like displayed on the WHRI website. This page will provide you with a space to help recruit participants, disseminate findings and showcase other knowledge translation activities resulting from the study. The content you provide in this form will be connected to the research team’s bios provided by the membership information. If any of these fields do not apply to this project, please leave them blank.

If there are supporting documents you would like embedded on the project page (i.e. consent forms) or if you have any questions regarding this form, please contact Nicole Prestley at Nicole.Prestley@cw.bc.ca or by phone **604-875-2424 ext 4956**.

|  |  |
| --- | --- |
| **Title:** (same as consent form) | A phase IIIb, open, multi-centre gynaecological extension study for the follow-up of a subset of HPV-015 study subjects |
| **Principal Investigator:** | Dr. Deborah Money |
| **Primary Contact:**(name, title, phone, email) | Melissa Watt, Research Coordinator604-875-2404, ext 4878mwatt@cw.bc.ca |
| **About the Study:**(100 words or less plain language summary) | Participants who have already taken part in the HPV-015 research study with GlaxoSmithKline (GSK) Biologicals’ human papillomavirus (HPV) vaccine may have been identified as one of the women in the HPV-015 study who might need additional gynecological follow-up either because: * their test for oncogenic (cancer causing) HPV infection was positive and their Pap smear test was normal at your concluding HPV-015 study visit, or
* they were pregnant at their final HPV-015 study visit and no cervical sample was taken at that time.
 |
| **Why is this research important?** |  |
| **Study Status:**(e.g. recruiting, data analysis, manuscript development, complete) | Recruiting |
| **Who can participate:**(short description, attach consent form) | Participants who already took part in the HPV-015 research study with GlaxoSmithKline (GSK) Biologicals’ human papillomavirus (HPV) vaccine and did not have a Pap smear test at their concluding visit because they were pregnant or their test for oncogenic (cancer causing) HPV infection was positive and their Pap smear test was normal at their concluding HPV-015 visit. |
| **Study Results/Publication:** |  |
| **Co-Investigators:** | Dr. Dianne MillerDr. Julie van Schalkwyk |
| **Funded by:** | GlaxoSmithKline (GSK) |
| **Partners:** |  |
| **Other Attachments:**(e.g. Newsletters, videos) |  |